Recent advances in human stem cell-based modeling of Tuberous Sclerosis Complex.
Wardiya Afshar Saber, Mustafa Sahin
PMID 32075691WHAT IT FOUND
Stem cell models of Tuberous Sclerosis Complex reveal that timing of mTOR inhibition is critical: early treatment prevents differentiation defects, but later treatment cannot reverse established cell fate decisions.
This suggests a narrow developmental window for potential therapeutic intervention.
Key findings
01In 3D cortical spheroid models, rapamycin treatment during early development prevented neuronal differentiation defects caused by TSC2 loss, but later treatment could not reverse cell fate decisions that had already occurred.
02Removal of rapamycin after early treatment in these models caused mTORC1 hyperactivity to return, indicating that sustained inhibition may be required to prevent re-emergence of pathological signaling in differentiated cells.
03Heterozygous TSC2 mutations in patient-derived neurons disrupted development, but treatment with a rapamycin analogue failed to correct these differentiation defects, unlike the rescue seen in some homozygous models.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
This is a narrative review of basic science and preclinical modeling, not a clinical trial or observational study of patients. In vitro models may not fully recapitulate the complexity of human brain development or the systemic manifestations of TSC. Results from stem cell models have not yet been translated into clinical practice or proven to alter patient outcomes. There is variability in findings between different cell lines and differentiation protocols, complicating interpretation.
Declared interests
The work was supported by the National Institutes of Health (NIH) through extramural research grants.
The easy way to misread this
Do not interpret these in vitro findings as evidence that timing of rapamycin treatment can be adjusted in clinical practice to improve neurological outcomes in TSC patients. These are laboratory models of cellular development, and no clinical trial data is presented to support changing current treatment protocols based on this review.